Slide 1HEMOSTASISHEMOSTASIS (CONT.)Vessel Wall: Endothelial cellsSlide 5Vessel Wall (cont.)Response to Vessel Wall Injury: Platelet adhesion and activationSlide 8Response to Vessel Wall Injury: VasoconstrictionSlide 10PLATELETS (CONT.)Slide 12Slide 13Slide 14Slide 15Slide 16Slide 17Slide 18Slide 19Disorders of Platelet Adhesion or AggregationVessel Wall DefectsPlatelet DefectsOther DefectsAntiplatelet DrugsSlide 25Hemostasis & Thrombosis: Platelet DisordersBeth A. BouchardBIOC 212: Biochemistry of Human DiseaseSpring 2005HEMOSTASISHemorrhageThrombosisHemostasisHEMOSTASIS (CONT.)1). INITIATIONVessel wall – endothelial cells and subendothelial components 2). LOCALIZATIONPlatelets – circulating cellular elements 3). PROPAGATION/AMPLIFICATIONPlasma coagulation proteins (factors)4). TERMINATIONPlasma coagulation protein inhibitors5). ELIMINATIONFibrinolytic systemVessel Wall: Endothelial cells•Physically separate platelets from subendothelial proteins that can induce platelet activation•Produce 2 potent vasodilators and inhibitors of platelet function: prostacyclin (prostaglandin I2, PGI2) and nitric oxideIncrease the concentration of the cyclic nucleotides cGMP and cAMP in platelets, which down regulate the signalling pathways that support platelet activation•Express CD39 on their surface, which enzymatically hydrolzes ADP, a potent platelet agonist release by activated plateletsVessel Wall (cont.)Response to Vessel Wall Injury: Platelet adhesion and activation•Exposure of flowing blood and platelets to subendothelial components•Platelets bind to the subendothelial collagen bound to von Willebrand factor (vWF), which is secreted from endothelial cells directly into the subendothelial space or adsorbed from plasma following endothelial cell secretion•vWf also binds directly to platelets via glycoprotein Ib-IX•Platelet interactions with collagen (via a specific platelet membrane receptor) and platelet activating factor (PAF), from the vessel wall, leads to their activationPlatelets adhered to damaged endotheliumResponse to Vessel Wall Injury: Vasoconstriction•Temporarily reduces local blood flow and hence, blood loss•Mediated in part by serotonin and thromboxane A2 (TXA2) from activated plateletsSerotonin is released from platelet dense granulesTXA2 is a product of platelet prostaglandin metabolismPLATELETSPLATELETS (CONT.)Platelet plugPlatelet Plug Formation = 1° hemostasisPlatelet Plug Formation: Platelet activation•Bind to subendothelial proteins and associated vWF subsequent to blood vessel injury•Activated via their interaction with collagen and PAF• Additional platelet agonists include ADP, epinephrine, thrombin, immune complexes, and high shear stress – all of the compounds interact with specific platelet membrane receptors•Several platelet activation pathways are initiatedPlatelet Plug Formation: Platelet activation events•Platelet shape change: extend pseudopodia, which facilitates aggregation and coagulant activity•Release of alpha and dense granule contents including a number of compounds involved in hemostasis• AggregationActivated plateletsPlatelet Plug Formation: Platelet aggregation•Platelet activation results in the functional expression of membrane receptors normally expressed in a non-functional state (glycoprotein IIb-IIIa)•Fibrinogen from the plasma or released from activated platelet alpha-granules binds to activated glycoprotein IIb-IIIa membrane receptors effectively bridging platelets to each otherPlatelets adhered to and aggregated upon collagenPlatelet Plug FormationPlatelet Plug Formation•Measured clinically as the bleeding time•Normal bleeding time is from 2 – 10 min•Usually the bleeding time is sufficient to detect defects of platelet adhesion and aggregation, in which it is prolongedDisorders of Platelet Adhesion or Aggregation•Affecting constituents of the vessel wall•Affecting the ability of the platelet to interact with the subendothelium at sites of blood vessel injury•Affecting the ability of the platelet to interact with other plateletsVessel Wall Defects•von Willebrand’s disease: a group of autosomal dominant disorders that result in reduced or abnormal synthesis of vWF •Defects in collagen synthesisEhlers-Danlos Syndrome: congenital defect in collagen synthesisScurvy: results from vitamin C (ascorbic acid) deficiency, which is involved in collagen synthesisExcess exogenous or endogenous corticosteroids: also leads to acquired deficiency in collagen synthesisPlatelet Defects•Bernard-Soulier Syndrome: expression of low levels of or defective glycoprotein Ib-IX on the platelet surface •Glanzmann’s thrombasthenia: expression of low levels of or defective glycoprotein IIb-IIIa on the platelet surfaceOther Defects•Fibrinogen: deficiency or production of abnormal protein•Acquired disorders include low platelet count (thrombocytopenia) as a result of defective formation of platelets by the bone marrow or excessive destruction of plateletsAntiplatelet